Screener
Jazz Pharmaceuticals JAZZ Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Intangible asset amortization | 172.3 | 154.4 |
| Gain on sale of priority review voucher | (122.8) | — |
| Total operating expenses | 732.3 | 953.7 |
| Income (loss) from operations | 336.6 | (55.9) |
| Interest expense, net | (39.9) | (53.7) |
| Foreign exchange gain (loss) | 2.5 | (0.2) |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 299.2 | (109.8) |
| Income tax expense (benefit) | 6.1 | (17.8) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's operating income?
- Jazz Pharmaceuticals (JAZZ) reported operating income of $336.6M in Q1 2026.
- How has Jazz Pharmaceuticals's operating income changed year-over-year?
- Jazz Pharmaceuticals's operating income increased by 702.1% year-over-year, from -$55.9M to $336.6M.
- What is the long-term trend for Jazz Pharmaceuticals's operating income?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's operating income has grown at a 61.5% compound annual growth rate (CAGR), from $170.28M to $716.63M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Jazz Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude